Kadmon Holdings Inc. (NYSE:KDMN) and Emmaus Life Sciences Inc. (OTCMKTS:EMMA), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation of the two firms.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Kadmon Holdings Inc.||2||447.62||N/A||-0.31||0.00|
|Emmaus Life Sciences Inc.||7||7.25||N/A||-7.78||0.00|
Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.
Table 2 provides the return on equity, net margins and return on assets of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|Kadmon Holdings Inc.||0.00%||-41.6%||-18.2%|
|Emmaus Life Sciences Inc.||0.00%||-313.7%||-215.9%|
3.9 and 3.9 are the respective Current Ratio and a Quick Ratio of Kadmon Holdings Inc. Its rival Emmaus Life Sciences Inc.’s Current and Quick Ratios are 0.8 and 0.8 respectively. Kadmon Holdings Inc. has a better chance of clearing its pay short and long-term debts than Emmaus Life Sciences Inc.
In next table is given Kadmon Holdings Inc. and Emmaus Life Sciences Inc.’s ratings and recommendations.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Kadmon Holdings Inc.||0||0||1||3.00|
|Emmaus Life Sciences Inc.||0||0||0||0.00|
The average price target of Kadmon Holdings Inc. is $8, with potential upside of 173.97%.
Insider and Institutional Ownership
The shares of both Kadmon Holdings Inc. and Emmaus Life Sciences Inc. are owned by institutional investors at 75.9% and 8.7% respectively. Insiders held 0.43% of Kadmon Holdings Inc. shares. Insiders Comparatively, held 10.5% of Emmaus Life Sciences Inc. shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Kadmon Holdings Inc.||-0.76%||15.42%||12.93%||15.42%||-21.79%||25.96%|
|Emmaus Life Sciences Inc.||29.94%||-22.5%||-15.56%||-44.9%||-41.67%||48.22%|
For the past year Kadmon Holdings Inc. has weaker performance than Emmaus Life Sciences Inc.
On 6 of the 8 factors Kadmon Holdings Inc. beats Emmaus Life Sciences Inc.
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics within autoimmune and fibrotic, oncology, and genetic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including those indicated for the management of rare diseases. Its lead product candidates include KD025, a rho-associated coiled-coil kinase2 inhibitor, which is in Phase II clinical studies for the treatment of autoimmune, fibrotic, and neurodegenerative diseases; Tesevatinib, an oral tyrosine kinase inhibitor that is in Phase II clinical studies for use in the treatment of non-small cell lung cancer and glioblastoma, as well as for treating autosomal dominant polycystic kidney disease; and KD034 that is used for the treatment of WilsonÂ’s disease, a genetic liver disease. Kadmon Holdings, Inc. has a strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Chiromics, LLC; VIVUS, Inc.; MeiraGTx Limited; AbbVie Inc.; Zydus Pharmaceuticals USA, Inc.; Jinghua Pharmaceutical Group Co., Ltd.; and Camber Pharmaceuticals, Inc. The company is headquartered in New York, New York.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.